Few prospective studies have systematically evaluated the extent of recovery from incident acquired demyelinating syndromes (ADS) of the central nervous system in children.
WHAT'S KNOWN ON THIS SUBJECT:
Most prospective cohort studies of acquired demyelinating syndromes in children have focused on the genetic, environmental, and neuroimaging predictors of multiple sclerosis. Less is known regarding the severity of the incident demyelinating event and predictors of residual attack-related physical disability.
WHAT THIS STUDY ADDS:
In a national, prospective longitudinal study, incident acquired demyelinating syndromes in children were characterized in terms of physical deficits and acuity at onset, and recovery over the first 12 months. Follow-up evaluations up to 10 years' postonset were analyzed. Acquired demyelinating syndromes (ADS) of the central nervous system (CNS) include optic neuritis (ON), transverse myelitis (TM), other monofocal demyelination (neurologic deficits referable to a single CNS lesion), acute disseminated encephalomyelitis (ADEM [defined according to polyfocal deficits accompanied by encephalopathy]), or polyfocal demyelination (deficits localized to .1 CNS location) without encephalopathy. 1 Most prospective cohort studies of ADS in children have focused on the genetic, environmental, and neuroimaging predictors of multiple sclerosis (MS). [2] [3] [4] [5] Relatively less is known regarding the severity of the acute incident demyelinating event and the predictors of residual attack-related physical disability.
In a national, prospective longitudinal study, we characterized incident ADS in children in terms of physical deficits at onset, clinical management, duration of hospitalization, and recovery over the first 12 months. Follow-up evaluations up to 10 years' postonset were analyzed to ascertain final diagnosis (MS or monophasic demyelination), evaluate stability of recovery beyond 12 months, and note new deficits among patients with MS.
METHODS
As detailed previously, 2 children aged ,16 years who met the criteria for ADS (Supplemental Table 4 ) were enrolled at 1 of 16 Canadian pediatric or 7 regional health care facilities within 90 days of symptom onset. Ethics approval was obtained at all sites. Parents or legal guardians signed informed consent forms, and younger children provided assent.
Patients were removed from the analysis if they withdrew after enrollment and requested data destruction or if they met the diagnostic criteria for neuromyelitis optica or nondemyelinating disorders. 6 All 283 children included in this analysis were seronegative for antibodies directed against aquaporin-4. 7 Clinical diagnosis data were censored as of the last study visit.
Site investigators attended training sessions and used standardized case report forms to record physical examination findings (Supplemental Appendix), as well as a priori criteria independent of MRI findings to confirm each patient's categorization according to the ADS presentations (Supplemental Table 4 ). One investigator (B.B.) reviewed all case report forms for accuracy of the ADS designation, and trained staff entered data centrally. Nerve or spinal cord involvement occurring in the context of ADEM or polyfocal demyelination was described as a component of these ADS presentations. Relapses were defined as new neurologic deficits persisting for 24 hours, confirmed by neurologic examination. When available, total white blood cell count in cerebrospinal fluid, protein, and presence in the cerebrospinal fluid of oligoclonal bands were recorded.
All participants were offered standardized research brain MRI studies at baseline; 3, 6, and 12 months; and annually thereafter. Brain and spine scans performed were also evaluated. All scans were anonymized and analyzed centrally. MRI scans that could not be assessed due to artifact from excessive patient motion or dental hardware were excluded. T2 lesions were defined as regions of increased T2 intensity .3 mm in cross-sectional diameter, and their presence or absence on baseline MRI of the brain and spine were noted. Lesions with regional mass effect or perilesional edema were reviewed to exclude malignancy. Longitudinally extensive transverse myelitis (LETM), defined as lesions extending 3 spinal segments, was noted on MRI. Serial scans were evaluated for the presence of new T2 or T1 gadolinium-enhancing lesions according to criteria for lesion dissemination in time. 8 Neurologic impairment was assessed quarterly in the first year, and annually thereafter, by using a descriptive scale of clinical severity within the same 8 functional systems (mobility, cognition, vision, pyramidal, cerebellar, brainstem, bowel and bladder, and sensory functions) (Supplemental Appendix) as on the Expanded Disability Status Scale. 9 This scale was not used because most of the pediatric neurologists were not sufficiently familiar with its adjudication. Treatments, the requirement for hospitalization, and the corresponding length of stay were recorded for each child.
Extent of recovery is reported for examinations at all time points within the first 12 months. Evaluations beyond 12 months' postonset were used for this analysis to ascertain diagnoses (MS versus monophasic ADS), comment on stability of recovery, and to note clinical deficits that occurred due to subsequent relapses in the patients with MS. We chose 12 months to maximize retention of participants and to reduce the likelihood of deficits due to subsequent attacks or early progressive disability in MS patients (secondary disease progression in pediatric-onset MS typically does not occur within the first years after onset). 10 Cognition was dichotomized according to the presence or absence of encephalopathy. Physical deficit severity was categorized (defined in Supplemental Table 5 ) for each patient, and overall severity was graded according to the most severe deficit observed in 1 of the following: mobility (pyramidal and cerebellar gait dysfunction), vision, or bowel and bladder function. Of the remaining domains, sensory deficits are not reported in terms of severity because they are too subjective, and isolated brain stem dysfunction occurred too rarely to contribute to an evaluation of severity. If patients experienced bilateral ON, the visual loss of the more severely affected eye was reported. Patients were considered to have experienced full physical recovery if they had normal gait, were considered to be back to baseline cognitively with resolution of encephalopathy (formal cognitive evaluations were not performed), if they had a corrected visual acuity of 20/20 in both eyes (as measured by using high-contrast visual acuity testing), and if they did not experience any difficulties with bowel or bladder control. 
RESULTS

Characteristics of Participants
Between September 1, 2004, and June 30, 2010, a total of 332 children were enrolled, and 283 were included in this analysis (Fig 1) . Table 1 Lumbar puncture was performed in 213 (75%) children (Table 1) . Clinicians were more likely to obtain
FIGURE 1
Study participants. Of 332 patients enrolled, 283 were analyzed in the current study. a One patient with MS was excluded because of severe and atypical attacks that have prompted investigation for an alternative diagnosis. Four of the patients who were included in the MS cohort in our previous research 2 were excluded from the present analysis: 2 children withdrew and asked that all of their data be destroyed; 1 child with severe CNS demyelination initially meeting criteria for MS developed progressive neurologic deterioration, and autopsy confirmed a mitochondrial encephalopathy associated with white matter lesions; and 1 child initially classified as having MS has developed new-onset systemic autoimmune features and is being assessed for systemic lupus erythematosus.
spinal fluid in children with ADEM. Brain MRIs were available for 269 children and MRI spine scans for 83 children. The frequencies of cerebrospinal fluid oligoclonal bands and MRI abnormalities varied according to ADS presentation.
Clinical Severity
Hospitalization was required for 244 children (86.2%), with a median (IQR) length of stay of 6 (3-10) days. Children with ADEM had the longest hospital stays, whereas children with ON had the shortest hospital stays ( Severe deficits in $1 feature of vision, motor, bladder and bowel function, or cognition were detected at ADS onset in 133 (47.0%) of 283 children, whereas 51 (18.0%) children had $1 moderate deficit, and 79 (27.9%) children had at least 1 mild deficit (Supplemental Fig 3A) . Twenty (7.1%) children had a normal examination at study enrollment (days from onset, median [range]: 9 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] ); all had at least 1 deficit at onset verified according to records review of their presenting examination.
Sixty-nine (24.4%) of 283 patients met the diagnostic criteria for ADEM at presentation, 11 of whom experienced concurrent TM and 4 of (Table 3) , which remained true even when children with ADEM were excluded.
Supplemental Figs 3A and 3B compare clinical severity at onset and the extent of recovery of the 281 children who were examined beyond their initial enrollment in the study (2 patients declined all follow-up) and provide detailed information regarding the 27 (10.0%) children who did not recover completely from their incident attack. Residual impairment from the incident ADS event was more common in female subjects (female:male ratio of 2.2:1), in children with TM, in children with more severe deficits at onset, and in those with a monophasic illness ( half of these children experienced a second clinical attack in the first year.
Our findings are similar to the 90% recovery reported for 296 pediatric ADS patients in the KIDMUS study in France. 4 In a cohort of 88 German children with MS, 80 had complete recoveries after their incident attacks. 12 We previously assessed 36 children with ON and found that full visual recovery occurred in 39 of 47 affected eyes, despite 69% having a visual deficit worse than or equal to 20/200 at onset. 13 Clinical recovery occurred quickly in our patients, with normalization of the neurologic examination by 3 months in nearly all children; a small number of children demonstrated further improvement at 12 months, and 7 children improved further beyond 12 months. ADS severity at onset was associated with the risk of residual deficits; however, most children with severe deficits recovered. Although the diagnosis of MS is considered a poor outcome, patients with MS had milder deficits at onset compared with children with monophasic disease, and all recovered from their incident attack. Consistent with these findings, data from patients with adult-onset MS have shown that MS patients initially presenting with TM have milder deficits than adults with monophasic TM. 14 Younger children were more likely to experience a severe presentation, as also noted in the study from Germany. 12 Although some of this relationship was driven by the higher frequency of ADEM at younger ages, younger age remained associated with severity at onset even when the children with ADEM were excluded. However, age at onset did not predict residual physical impairment from the acute attack, which may suggest a strong capacity for neurologic repair of acute lesions in the youngest patients.
Of the 102 patients with TM in our study, 15 (14.7%) were left with residual motor impairment, 8 (7.8%) of whom require a wheelchair and 13 (12.7%) have residual bladder impairment. We previously described 38 children with TM (none included in the present analysis); 6 (16%) experienced residual motor impairment and 8 (22%) experienced residual bladder impairment. 15 In a European study of 95 children with TM, 28 (30%) experienced a poor outcome (defined as Expanded Disability Status Scale score $4). 16 Of 47 children reported from the Johns Hopkins Myelitis Center, 17 ten (21%) patients required a walker or other support and 22 (50%) of 44 required bladder catheterization. The slightly higher proportion of TM patients with severe deficits in the Hopkins center may reflect referral bias to a dedicated TM program. Of interest in our study was that LETM did not predict more severe disability; however, we excluded 3 children with neuromyelitis optica in whom LETM is typically clinically severe.
Given the common practice of corticosteroid therapy (provided to 82% of our cohort), we cannot evaluate the contribution of corticosteroid exposure to outcome. Although randomized trials would provide evidence to support or refute the role of corticosteroids in acute management of ADS, endorsement of such a study is unlikely given the severity of acute illness and the strong international consensus regarding at least its short-term benefit. 18, 19 There are limitations to our study. First, children with mild symptoms of ADS may have been missed; our research thus delineates the clinical severity and outcome of children unwell enough to seek medical attention. Our national network mitigates concerns regarding referral to specialized MS centers, and our network has .95% ascertainment of all children with ADS seen by Canadian pediatric health care providers. 20 
